Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Withdrawn 1Active not recruiting 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Dermatologic 3Tumor-Agnostic 2Thoracic 2Head & Neck 2Gastrointestinal 2Sarcoma 1Gynecologic 1Genitourinary 1CNS 1

Conditions

Squamous Cell Carcinoma of Head and Neck 1Lymphoid Interstitial Pneumonia 1Laryngeal Diseases 1Head and Neck Neoplasms 1Carcinoma, Squamous Cell 1

Interventions

Cisplatin 620pembrolizumab 323Radiotherapy 319Cetuximab 275Docetaxel 221Radiotherapy, Intensity-Modulated 210Carboplatin 197Fluorouracil 196Paclitaxel 159Nivolumab 138Gemcitabine 124Magnetic Resonance Spectroscopy 94Radiation 85Drug Therapy 77Capecitabine 76toripalimab 75Surgical Procedures, Operative 62durvalumab 60Biopsy 52Cyclophosphamide 50Chemoradiotherapy 47camrelizumab 46Specimen Handling 46Erlotinib Hydrochloride 46Radiosurgery 45130-nm albumin-bound paclitaxel 44Standard of Care 43tislelizumab 42Platinum 41Bevacizumab 40

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Interventional × linrodostat × Head & Neck × Clear all
NCT03854032 2025-06-06

Nivolumab and BMS986205 in Treating Patients With Stage II-IV Squamous Cell Cancer of the Head and Neck

Thomas Jefferson University

Phase 2 Active not recruiting
45 enrolled
Head & Neck

Lymphoid Interstitial Pneumonia, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Laryngeal Diseases

NCT03386838 2019-04-18

An Immuno-therapy Study of Nivolumab in Combination With Experimental Medication BMS-986205 Compared to Standard of Care EXTREME Regimen in First-line Recurrent/Metastatic Squamous Cell Carcinoma of Head and Neck

Bristol-Myers Squibb

Phase 3 Withdrawn
Head & Neck

Head and Neck Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡